Education
About Us
Working with TipRanks
Follow Us
Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
ARTV Stock Chart & Stats
$5.74
$0.32(3.02%)
At close: 4:00 PM EST
$5.74
$0.32(3.02%)
Day’s Range― - ―
52-Week Range$1.47 - $7.36
Previous CloseN/A
Volume23.16K
Average Volume (3M)153.04K
Market Cap
$140.89M
Enterprise Value$127.07M
Total Cash (Recent Filing)$122.97M
Total Debt (Recent Filing)$11.69M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Mar 30, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding24,544,905
10 Day Avg. Volume167,768
30 Day Avg. Volume153,041
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.32
Price to Sales (P/S)978.41
P/FCF Ratio-4.41
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-191.95
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$19.00Price Target Upside231.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.36
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Allogeneic (off-the-shelf) NK PlatformAn allogeneic, off-the-shelf NK cell model is a durable strategic asset: it can enable scalable manufacturing and repeat dosing versus autologous approaches, broaden potential partner and payer interest, and support faster commercial rollout if clinical and regulatory milestones are met.
Positive AlloNK Clinical DataInitial safety and translational signals materially reduce clinical and regulatory risk for the AlloNK program. Demonstrated outpatient feasibility and consistent biological effect strengthen the program's commercial thesis and support planned FDA interactions in 2026, improving long-term development prospects.
Low Leverage And Positive EquityModest debt and a return to positive equity provide balance sheet flexibility relative to highly leveraged peers. This reduces near-term insolvency risk and supports the ability to raise funds or partner programs without the immediate pressure of high fixed financial obligations.
Bears Say
Revenue CollapseA complete collapse of revenue and loss of operational scale materially weakens the company's ability to self-fund R&D and commercial activities. Absent new revenue streams, this elevates dependence on capital markets or partners and increases long-term execution risk.
Severe Cash BurnHigh negative operating and free cash flow indicate substantial ongoing financing needs. Persistent cash burn shortens runway, increases dilution or covenant risk from financings, and constrains strategic optionality for clinical programs over the coming months.
Large Persistent LossesSustained, sizable net losses and negative returns on equity signal that profitability is distant. Continued losses limit reinvestment capacity, pressure cash reserves, and raise the probability of disruptive financing or program cutbacks absent milestone-based partnerships.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $1.47 and its highest was $7.36 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $140.89M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Mar 30, 2026 which is in 23 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Nov 12, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.868 by -$0.012.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.84.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,544,905 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.868. Following the earnings report the stock price went up 10.864%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (231.01% Upside)
$19.00 (231.01% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.83%
12-Months-Change
Fundamentals
Return on Equity
-47.96%
Trailing 12-Months
Asset Growth
-34.01%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$19.00
▲(231.01% Upside)
Technical Analysis
Ownership Overview
11.37% Insiders
1.81% Mutual Funds
0.50% Other Institutional Investors
85.42% Public Companies and Individual Investors
Options Prices
Currently, No data available
---